Sepracor Resubmits Estorra NDA; Expected Approval Pushed To Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects FDA will take six months to review the eszopiclone resubmission. Sepracor had earlier expressed optimism about a two-month review, which would have set an approval target for the sleep agent around mid-year.
You may also be interested in...
Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate
Reviewing division's "not approvable" recommendation is overruled by Office Director Temple, FDA review documents show.
Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate
Reviewing division's "not approvable" recommendation is overruled by Office Director Temple, FDA review documents show.
Takeda Sales Force Size For Ramelteon Will Depend On Competitor Detailing
To develop a launch strategy for the insomnia agent, Takeda says it will consider the promotional efforts for Sepracor's Lunesta and for indiplon, which Pfizer and Neurocrine expect to refile with FDA in March/April. Takeda predicts a fall launch for ramelteon.